Background Activating mutations of EZH2, an epigenetic regulator, are present in approximately
20% of patients with follicular lymphoma. We investigated the activity and safety of …

The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid
malignancies provided proof-of-principle for exploiting the immune system therapeutically. …

Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need.
Here we report the primary analysis of a phase 1b/2 trial of outpatient mosunetuzumab (a …

PURPOSE Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to
CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 …

Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome
are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In …

Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data
guiding management are limited. We describe outcomes and features following CAR-T …

Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell
lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. …

Background: CD19 CAR T cells have demonstrated high response rates in patients (pts) with
relapsed or refractory (R/R) lymphoma, but these therapies are associated with high rates …

Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from
antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most …

Background: CD19-specific 2 nd generation chimeric antigen receptor (CAR) T cell therapy
with either CD28 or 41BB co-stimulatory domain has demonstrated complete remission (CR) …